Inhalant use, unspecified with intoxication, unspecified
ICD-10 F18.929 is a billable code used to indicate a diagnosis of inhalant use, unspecified with intoxication, unspecified.
F18.929 refers to inhalant use disorder characterized by the consumption of volatile substances that produce psychoactive effects. Inhalants include a wide range of substances such as solvents, aerosols, and gases, which are often easily accessible and can lead to significant health risks. Intoxication from inhalants can result in symptoms such as euphoria, dizziness, hallucinations, and impaired judgment. Chronic use can lead to severe physical and psychological dependence, withdrawal symptoms, and long-term damage to the brain and other organs. Treatment typically involves a combination of behavioral therapies, counseling, and support groups, as there are no specific pharmacological treatments approved for inhalant use disorder. The unspecified nature of this code indicates that the clinician has not provided specific details regarding the type of inhalant used or the severity of intoxication, which can complicate treatment and management strategies.
Detailed history of substance use, including types of inhalants and frequency of use.
Patients presenting with acute intoxication, withdrawal symptoms, or complications from chronic inhalant use.
Consideration of co-occurring mental health disorders and the need for a multidisciplinary treatment approach.
Comprehensive psychiatric evaluation, including mental status examination and risk assessment.
Patients with behavioral issues related to inhalant use, such as aggression or mood swings.
Assessment of underlying psychiatric conditions that may contribute to substance use.
Used when assessing a patient for inhalant use disorder.
Document the assessment findings and recommendations.
Addiction specialists should ensure comprehensive evaluations.
Document the patient's history of inhalant use, symptoms experienced during intoxication, and any treatment provided. Include details about the frequency and quantity of inhalant use, as well as any co-occurring mental health issues.
